{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:02:47Z","timestamp":1779951767978,"version":"3.53.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["223047\/Z\/21\/Z"],"award-info":[{"award-number":["223047\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s13555-026-01784-0","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:37:24Z","timestamp":1778315844000},"page":"2363-2376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapies for Infantile Haemangiomas: Current Practice and Evolving Perspectives"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5259-2878","authenticated-orcid":false,"given":"B.","family":"Nolan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7084-5293","authenticated-orcid":false,"given":"C.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"2","key":"1784_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1525-1470.2008.00626.x","volume":"25","author":"C Kilcline","year":"2008","unstructured":"Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol. 2008;25(2):168\u201373. https:\/\/doi.org\/10.1111\/j.1525-1470.2008.00626.x.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"1784_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1542\/peds.2007-2767","volume":"122","author":"LC Chang","year":"2008","unstructured":"Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122(2):360\u20137. https:\/\/doi.org\/10.1542\/peds.2007-2767.","journal-title":"Pediatrics"},{"issue":"1","key":"1784_CR3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-3475","volume":"143","author":"DP Krowchuk","year":"2019","unstructured":"Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143(1):e20183475. https:\/\/doi.org\/10.1542\/peds.2018-3475.","journal-title":"Pediatrics"},{"issue":"10089","key":"1784_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0140-6736(16)00645-0","volume":"390","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2017","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390(10089):85\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(16)00645-0.","journal-title":"Lancet"},{"issue":"4","key":"1784_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1542\/peds.85.4.491","volume":"85","author":"O Enjolras","year":"1990","unstructured":"Enjolras O, Riche MC, Merland JJ, Escande JP. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics. 1990;85(4):491\u20138.","journal-title":"Pediatrics"},{"issue":"22","key":"1784_CR6","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199205283262203","volume":"326","author":"RA Ezekowitz","year":"1992","unstructured":"Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992;326(22):1456\u201363. https:\/\/doi.org\/10.1056\/NEJM199205283262203.","journal-title":"N Engl J Med"},{"issue":"24","key":"1784_CR7","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1056\/NEJMc0708819","volume":"358","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Ta\u00efeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649\u201351. https:\/\/doi.org\/10.1056\/NEJMc0708819.","journal-title":"N Engl J Med"},{"issue":"8","key":"1784_CR8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa1404710","volume":"372","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1404710.","journal-title":"N Engl J Med"},{"issue":"2","key":"1784_CR9","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1542\/peds.2010-0029","volume":"128","author":"M Hogeling","year":"2011","unstructured":"Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011;128(2):e259\u201366. https:\/\/doi.org\/10.1542\/peds.2010-0029.","journal-title":"Pediatrics"},{"issue":"4","key":"1784_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1001\/jamaoto.2013.6723","volume":"140","author":"NM Bauman","year":"2014","unstructured":"Bauman NM, McCarter RJ, Guzzetta PC, et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2014;140(4):323\u201330. https:\/\/doi.org\/10.1001\/jamaoto.2013.6723.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"4","key":"1784_CR11","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/lary.20807","volume":"120","author":"LM Buckmiller","year":"2010","unstructured":"Buckmiller LM, Munson PD, Dyamenahalli U, Dai Y, Richter GT. Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. Laryngoscope. 2010;120(4):676\u201381. https:\/\/doi.org\/10.1002\/lary.20807.","journal-title":"Laryngoscope"},{"issue":"3","key":"1784_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/PRS.0b013e31827c6fab","volume":"131","author":"A Izadpanah","year":"2013","unstructured":"Izadpanah A, Izadpanah A, Kanevsky J, Belzile E, Schwarz K. Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis. Plast Reconstr Surg. 2013;131(3):601\u201313. https:\/\/doi.org\/10.1097\/PRS.0b013e31827c6fab.","journal-title":"Plast Reconstr Surg"},{"issue":"11","key":"1784_CR13","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1001\/jamadermatol.2021.3479","volume":"157","author":"AA Endicott","year":"2021","unstructured":"Endicott AA, Chamlin SL, Drolet BA, et al. Mapping of segmental and partial segmental infantile hemangiomas of the face and scalp. JAMA Dermatol. 2021;157(11):1328\u201334. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3479.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1784_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006545.pub3","volume":"4","author":"M Novoa","year":"2018","unstructured":"Novoa M, Baselga E, Beltran S, et al. Interventions for infantile haemangiomas of the skin. Cochrane Database Syst Rev. 2018;4(4):CD006545. https:\/\/doi.org\/10.1002\/14651858.CD006545.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1784_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2133.2010.09848.x","volume":"163","author":"CH Storch","year":"2010","unstructured":"Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 2010;163(2):269\u201374. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09848.x.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1784_CR16","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1002\/pbc.25453","volume":"62","author":"WK Pan","year":"2015","unstructured":"Pan WK, Li P, Guo ZT, Huang Q, Gao Y. Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K\/Akt\/eNOS\/VEGF pathway. Pediatr Blood Cancer. 2015;62(8):1414\u201320. https:\/\/doi.org\/10.1002\/pbc.25453.","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"1784_CR17","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.jpedsurg.2012.09.008","volume":"47","author":"Y Ji","year":"2012","unstructured":"Ji Y, Li K, Xiao X, Zheng S, Xu T, Chen S. Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. J Pediatr Surg. 2012;47(12):2216\u201323. https:\/\/doi.org\/10.1016\/j.jpedsurg.2012.09.008.","journal-title":"J Pediatr Surg"},{"issue":"1","key":"1784_CR18","first-page":"48","volume":"7","author":"L Zhang","year":"2013","unstructured":"Zhang L, Mai HM, Zheng J, et al. Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell. Int J Clin Exp Pathol. 2013;7(1):48\u201355.","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"1784_CR19","doi-asserted-by":"publisher","DOI":"10.4161\/19381980.2014.979699","volume":"6","author":"JJ Kum","year":"2015","unstructured":"Kum JJ, Khan ZA. Mechanisms of propranolol action in infantile hemangioma. Dermatoendocrinol. 2015;6(1):e979699. https:\/\/doi.org\/10.4161\/19381980.2014.979699.","journal-title":"Dermatoendocrinol"},{"issue":"2","key":"1784_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/JOVA.0000000000000113","volume":"6","author":"DC Goldenberg","year":"2025","unstructured":"Goldenberg DC, Vikkula M, Penington A, et al. Updated classification of vascular anomalies. A living document from the International Society for the Study of Vascular Anomalies Classification Group. J Vasc Anomalies. 2025;6(2):e113. https:\/\/doi.org\/10.1097\/JOVA.0000000000000113.","journal-title":"J Vasc Anomalies"},{"issue":"4","key":"1784_CR21","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-1628","volume":"145","author":"C L\u00e9aute-Labr\u00e8ze","year":"2020","unstructured":"L\u00e9aute-Labr\u00e8ze C, Baselga Torres E, Weibel L, et al. The Infantile Hemangioma Referral Score: a validated tool for physicians. Pediatrics. 2020;145(4):e20191628. https:\/\/doi.org\/10.1542\/peds.2019-1628.","journal-title":"Pediatrics"},{"issue":"3","key":"1784_CR22","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/bjd.16779","volume":"179","author":"L Solman","year":"2018","unstructured":"Solman L, Glover M, Beattie PE, et al. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines. Br J Dermatol. 2018;179(3):582\u20139. https:\/\/doi.org\/10.1111\/bjd.16779.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1784_CR23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/pde.15623","volume":"41","author":"CY Huang","year":"2024","unstructured":"Huang CY, Perman MJ, Yan AC. Regimen for accelerated propranolol initial dosing (RAPID). Pediatr Dermatol. 2024;41(4):621\u20137. https:\/\/doi.org\/10.1111\/pde.15623.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"1784_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.399","volume":"6","author":"L Del Frari","year":"2018","unstructured":"Del Frari L, L\u00e9aut\u00e9-Labr\u00e8ze C, Guibaud L, et al. Propranolol pharmacokinetics in infants treated for infantile hemangiomas requiring systemic therapy: modeling and dosing regimen recommendations. Pharmacol Res Perspect. 2018;6(3):e00399. https:\/\/doi.org\/10.1002\/prp2.399.","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"1784_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1001\/jama.2015.13969","volume":"315","author":"S Prey","year":"2016","unstructured":"Prey S, Voisard JJ, Delarue A, et al. Safety of propranolol therapy for severe infantile hemangioma. JAMA. 2016;315(4):413\u20135. https:\/\/doi.org\/10.1001\/jama.2015.13969.","journal-title":"JAMA"},{"issue":"4","key":"1784_CR26","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-0353","volume":"138","author":"C L\u00e9aute-Labr\u00e8ze","year":"2016","unstructured":"L\u00e9aute-Labr\u00e8ze C, Boccara O, Degrugillier-Chopinet C, et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics. 2016;138(4):e20160353. https:\/\/doi.org\/10.1542\/peds.2016-0353.","journal-title":"Pediatrics"},{"issue":"2","key":"1784_CR27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jaad.2020.04.013","volume":"85","author":"KB P\u00fcttgen","year":"2021","unstructured":"P\u00fcttgen KB, Hansen LM, Lauren C, et al. Limited utility of repeated vital sign monitoring during initiation of oral propranolol for complicated infantile hemangioma. J Am Acad Dermatol. 2021;85(2):345\u201352. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.013.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1784_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/pde.15740","volume":"42","author":"K Rypka","year":"2025","unstructured":"Rypka K, Bellefeuille G, Wendland Z, et al. Oral propranolol and its impact on vital signs in hospitalized pediatric patients for the management of infantile hemangiomas. Pediatr Dermatol. 2025;42(2):245\u201350. https:\/\/doi.org\/10.1111\/pde.15740.","journal-title":"Pediatr Dermatol"},{"issue":"7","key":"1784_CR29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/archdermatol.2010.158","volume":"146","author":"KE Holland","year":"2010","unstructured":"Holland KE, Frieden IJ, Frommelt PC, Mancini AJ, Wyatt D, Drolet BA. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol. 2010;146(7):775\u20138. https:\/\/doi.org\/10.1001\/archdermatol.2010.158.","journal-title":"Arch Dermatol"},{"issue":"12","key":"1784_CR30","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/archdermatol.2011.203","volume":"147","author":"CJ Price","year":"2011","unstructured":"Price CJ, Lattouf C, Baum B. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. Arch Dermatol. 2011;147(12):1371\u20136. https:\/\/doi.org\/10.1001\/archdermatol.2011.203.","journal-title":"Arch Dermatol"},{"issue":"5","key":"1784_CR31","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/pde.15652","volume":"41","author":"C O'Connor","year":"2024","unstructured":"O\u2019Connor C, Murphy M. The burden of treatment of propranolol for infantile hemangiomas: a mixed methods study. Pediatr Dermatol. 2024;41(5):838\u201340. https:\/\/doi.org\/10.1111\/pde.15652.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"1784_CR32","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1542\/peds.2011-3683","volume":"130","author":"MM Tollefson","year":"2012","unstructured":"Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents\u2019 photographs tell us. Pediatrics. 2012;130(2):e314\u201320. https:\/\/doi.org\/10.1542\/peds.2011-3683.","journal-title":"Pediatrics"},{"issue":"4","key":"1784_CR33","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-1754","volume":"137","author":"SD Shah","year":"2016","unstructured":"Shah SD, Baselga E, McCuaig C, et al. Rebound growth of infantile hemangiomas after propranolol therapy. Pediatrics. 2016;137(4):e20151754. https:\/\/doi.org\/10.1542\/peds.2015-1754.","journal-title":"Pediatrics"},{"issue":"6","key":"1784_CR34","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1684\/ejd.2021.4172","volume":"31","author":"E Baselga","year":"2021","unstructured":"Baselga E, El Hachem M, Diociaiuti A, et al. Sequelae following infantile haemangiomas treated with propranolol. Eur J Dermatol. 2021;31(6):785\u201390. https:\/\/doi.org\/10.1684\/ejd.2021.4172.","journal-title":"Eur J Dermatol"},{"issue":"11","key":"1784_CR35","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/cea.14401","volume":"53","author":"C O'Connor","year":"2023","unstructured":"O\u2019Connor C, Trujillo J, Murphy M. Prescribing propranolol for infants at risk of anaphylaxis. Clin Exp Allergy. 2023;53(11):1144\u20136. https:\/\/doi.org\/10.1111\/cea.14401.","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"1784_CR36","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jamadermatol.2021.0469","volume":"157","author":"E Fern\u00e1ndez Faith","year":"2021","unstructured":"Fern\u00e1ndez Faith E, Shah S, Witman PM, et al. Clinical features, prognostic factors, and treatment interventions for ulceration in patients with infantile hemangioma. JAMA Dermatol. 2021;157(5):566\u201372. https:\/\/doi.org\/10.1001\/jamadermatol.2021.0469.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1784_CR37","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jaad.2024.11.077","volume":"92","author":"A Finstad","year":"2025","unstructured":"Finstad A, Lytvyn Y, Pope E, Sibbald C. Safety of beta blockers for the treatment of PHACE syndrome: a systematic review. J Am Acad Dermatol. 2025;92(5):1107\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2024.11.077.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1784_CR38","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1001\/jamadermatol.2019.3839","volume":"156","author":"GM Olsen","year":"2020","unstructured":"Olsen GM, Hansen LM, Stefanko NS, et al. Evaluating the safety of oral propranolol therapy in patients with PHACE syndrome. JAMA Dermatol. 2020;156(2):186\u201390. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3839.","journal-title":"JAMA Dermatol"},{"key":"1784_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2024.114101","volume":"272","author":"D Metry","year":"2024","unstructured":"Metry D, Copp HL, Rialon KL, et al. Delphi consensus on diagnostic criteria for LUMBAR syndrome. J Pediatr. 2024;272:114101. https:\/\/doi.org\/10.1016\/j.jpeds.2024.114101.","journal-title":"J Pediatr"},{"issue":"3","key":"1784_CR40","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1177\/00034894221089758","volume":"132","author":"T Chen","year":"2023","unstructured":"Chen T, Gudipudi R, Nguyen SA, Carroll W, Clemmens C. Should propranolol remain the gold standard for treatment of infantile hemangioma? A systematic review and meta-analysis of propranolol versus atenolol. Ann Otol Rhinol Laryngol. 2023;132(3):332\u201340. https:\/\/doi.org\/10.1177\/00034894221089758.","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"7","key":"1784_CR41","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1001\/jamaoto.2021.0454","volume":"147","author":"Y Ji","year":"2021","unstructured":"Ji Y, Chen S, Yang K, et al. Efficacy and safety of propranolol vs atenolol in infants with problematic infantile hemangiomas: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2021;147(7):599\u2013607. https:\/\/doi.org\/10.1001\/jamaoto.2021.0454.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"1","key":"1784_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1001\/jamapediatrics.2021.4565","volume":"176","author":"E Pope","year":"2022","unstructured":"Pope E, Lara-Corrales I, Sibbald C, et al. Noninferiority and safety of nadolol vs propranolol in infants with infantile hemangioma: a randomized clinical trial. JAMA Pediatr. 2022;176(1):34\u201341. https:\/\/doi.org\/10.1001\/jamapediatrics.2021.4565.","journal-title":"JAMA Pediatr"},{"issue":"1","key":"1784_CR43","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-1035","volume":"145","author":"E McGillis","year":"2020","unstructured":"McGillis E, Baumann T, LeRoy J. Death associated with nadolol for infantile hemangioma: a case for improving safety. Pediatrics. 2020;145(1):e20191035. https:\/\/doi.org\/10.1542\/peds.2019-1035.","journal-title":"Pediatrics"},{"issue":"2","key":"1784_CR44","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1525-1470.2012.01723.x","volume":"30","author":"M Moehrle","year":"2013","unstructured":"Moehrle M, L\u00e9aut\u00e9-Labr\u00e8ze C, Schmidt V, R\u00f6cken M, Poets CF, Goelz R. Topical timolol for small hemangiomas of infancy. Pediatr Dermatol. 2013;30(2):245\u20139. https:\/\/doi.org\/10.1111\/j.1525-1470.2012.01723.x.","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"1784_CR45","doi-asserted-by":"publisher","first-page":"e1739","DOI":"10.1542\/peds.2012-3828","volume":"131","author":"H Chan","year":"2013","unstructured":"Chan H, McKay C, Adams S, Wargon O. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. Pediatrics. 2013;131(6):e1739\u201347. https:\/\/doi.org\/10.1542\/peds.2012-3828.","journal-title":"Pediatrics"},{"issue":"5","key":"1784_CR46","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1001\/jamadermatol.2021.0596","volume":"157","author":"FZ Mu\u00f1oz-Garza","year":"2021","unstructured":"Mu\u00f1oz-Garza FZ, R\u00edos M, Ro\u00e9-Crespo E, et al. Efficacy and safety of topical timolol for the treatment of infantile hemangioma in the early proliferative stage: a randomized clinical trial. JAMA Dermatol. 2021;157(5):583\u20137. https:\/\/doi.org\/10.1001\/jamadermatol.2021.0596.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1784_CR47","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/pde.12767","volume":"33","author":"L Weibel","year":"2016","unstructured":"Weibel L, Barysch MJ, Scheer HS, et al. Topical timolol for infantile hemangiomas: evidence for efficacy and degree of systemic absorption. Pediatr Dermatol. 2016;33(2):184\u201390. https:\/\/doi.org\/10.1111\/pde.12767.","journal-title":"Pediatr Dermatol"},{"key":"1784_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1515901","volume":"15","author":"X Huang","year":"2024","unstructured":"Huang X, Si W, Zou Z, et al. Efficacy and safety of oral propranolol and topical timolol in the treatment of infantile hemangioma: a meta-analysis and systematic review. Front Pharmacol. 2024;15:1515901. https:\/\/doi.org\/10.3389\/fphar.2024.1515901.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1784_CR49","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jaad.2004.09.004","volume":"52","author":"MC Garzon","year":"2005","unstructured":"Garzon MC, Lucky AW, Hawrot A, Frieden IJ. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol. 2005;52(2):281\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2004.09.004.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1784_CR50","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.bjps.2014.07.009","volume":"67","author":"JA Couto","year":"2014","unstructured":"Couto JA, Greene AK. Management of problematic infantile hemangioma using intralesional triamcinolone: efficacy and safety in 100 infants. J Plast Reconstr Aesthet Surg. 2014;67(11):1469\u201374. https:\/\/doi.org\/10.1016\/j.bjps.2014.07.009.","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"3","key":"1784_CR51","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/09546634.2019.1590521","volume":"31","author":"HH Sabry","year":"2020","unstructured":"Sabry HH, Sorour NE, Akl EM. Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma. J Dermatolog Treat. 2020;31(3):279\u201384. https:\/\/doi.org\/10.1080\/09546634.2019.1590521.","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"1784_CR52","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/archderm.140.7.867","volume":"140","author":"BJ Metz","year":"2004","unstructured":"Metz BJ, Rubenstein MC, Levy ML, Metry DW. Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol. 2004;140(7):867\u201370. https:\/\/doi.org\/10.1001\/archderm.140.7.867.","journal-title":"Arch Dermatol"},{"issue":"6","key":"1784_CR53","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1542\/peds.2006-2962","volume":"119","author":"E Pope","year":"2007","unstructured":"Pope E, Krafchik BR, Macarthur C, et al. Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial. Pediatrics. 2007;119(6):e1239\u201347. https:\/\/doi.org\/10.1542\/peds.2006-2962.","journal-title":"Pediatrics"},{"issue":"3 Pt 1","key":"1784_CR54","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/s0022-3476(98)70034-4","volume":"132","author":"CF Barlow","year":"1998","unstructured":"Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr. 1998;132(3 Pt 1):527\u201330. https:\/\/doi.org\/10.1016\/s0022-3476(98)70034-4.","journal-title":"J Pediatr"},{"issue":"11","key":"1784_CR55","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.ijporl.2010.07.014","volume":"74","author":"RS Glade","year":"2010","unstructured":"Glade RS, Vinson K, Becton D, Bhutta S, Buckmiller LM. Management of complicated hemangiomas with vincristine\/vinblastine: quantitative response to therapy using MRI. Int J Pediatr Otorhinolaryngol. 2010;74(11):1221\u20135. https:\/\/doi.org\/10.1016\/j.ijporl.2010.07.014.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"9332","key":"1784_CR56","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0140-6736(02)09741-6","volume":"360","author":"K Batta","year":"2002","unstructured":"Batta K, Goodyear HM, Moss C, Williams HC, Hiller L, Waters R. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1-year analysis. Lancet. 2002;360(9332):521\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(02)09741-6.","journal-title":"Lancet"},{"issue":"4","key":"1784_CR57","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jpedsurg.2018.08.001","volume":"54","author":"SF Polites","year":"2019","unstructured":"Polites SF, Watanabe M, Crafton T, et al. Surgical resection of infantile hemangiomas following medical treatment with propranolol versus corticosteroids. J Pediatr Surg. 2019;54(4):740\u20133. https:\/\/doi.org\/10.1016\/j.jpedsurg.2018.08.001.","journal-title":"J Pediatr Surg"},{"key":"1784_CR58","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.2147\/DDDT.S460575","volume":"18","author":"W Lu","year":"2024","unstructured":"Lu W, Yang Z, Wang M, Zhang Y, Qi Z, Yang X. Identification of potential therapeutics for infantile hemangioma via in silico investigation and in vitro validation. Drug Des Devel Ther. 2024;18:4065\u201388. https:\/\/doi.org\/10.2147\/DDDT.S460575.","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"1784_CR59","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3257","volume":"137","author":"DM Adams","year":"2016","unstructured":"Adams DM, Trenor CC 3rd, Hammill AM, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137(2):e20153257. https:\/\/doi.org\/10.1542\/peds.2015-3257.","journal-title":"Pediatrics"},{"issue":"6","key":"1784_CR60","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/pde.70071","volume":"42","author":"FCPS Lopes","year":"2025","unstructured":"Lopes FCPS, Levy ML, Ruth JS, Priola G, Greenberger S. Sirolimus in the management of complex infantile hemangiomas: a state-of-the-art review. Pediatr Dermatol. 2025;42(6):1126\u201332. https:\/\/doi.org\/10.1111\/pde.70071.","journal-title":"Pediatr Dermatol"},{"issue":"7","key":"1784_CR61","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.jid.2018.12.028","volume":"139","author":"S Chen","year":"2019","unstructured":"Chen S, Zhuang K, Sun K, et al. Itraconazole induces regression of infantile hemangioma via downregulation of the platelet-derived growth factor-D\/PI3K\/Akt\/mTOR pathway. J Invest Dermatol. 2019;139(7):1574\u201382. https:\/\/doi.org\/10.1016\/j.jid.2018.12.028.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1784_CR62","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1525-1470.2007.00573.x","volume":"25","author":"CC MacFie","year":"2008","unstructured":"MacFie CC, Jeffery SL. Diagnosis of vascular skin lesions in children: an audit and review. Pediatr Dermatol. 2008;25(1):7\u201312. https:\/\/doi.org\/10.1111\/j.1525-1470.2007.00573.x.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"1784_CR63","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519873490","volume":"48","author":"W Onsoi","year":"2020","unstructured":"Onsoi W, Chaiyarit J, Techasatian L. Common misdiagnoses and prevalence of dermatological disorders at a pediatric tertiary care center. J Int Med Res. 2020;48(2):300060519873490. https:\/\/doi.org\/10.1177\/0300060519873490.","journal-title":"J Int Med Res"},{"key":"1784_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1439449","volume":"11","author":"R Su","year":"2024","unstructured":"Su R, Qian H, Hu C, et al. Oral propranolol for the treatment of hemangiomas in high-risk infants: safety and cost analysis of outpatient-initiated therapy. Front Med. 2024;11:1439449. https:\/\/doi.org\/10.3389\/fmed.2024.1439449.","journal-title":"Front Med"},{"issue":"3","key":"1784_CR65","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1080\/09546634.2020.1808153","volume":"33","author":"A Flynn","year":"2022","unstructured":"Flynn A, O\u2019Connor C, Murphy M. Photo-triage of infantile hemangiomas: potential to reduce healthcare exposure in the COVID19 pandemic. J Dermatolog Treat. 2022;33(3):1775\u20136. https:\/\/doi.org\/10.1080\/09546634.2020.1808153.","journal-title":"J Dermatolog Treat"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01784-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:18:29Z","timestamp":1779949109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01784-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1784"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01784-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Brian Nolan and Cathal O\u2019Connor declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}